Table 2.
Association Between the Change of COX2, IL6, and IL1β Expression with 5-FU Therapy and the Clinic-Pathological Features of the Assessed CRC Patients
| COX2 | P-valuea | IL6 | P-valuea | IL1β | P-valuea | ||||
|---|---|---|---|---|---|---|---|---|---|
| Decrease (n=64) | Increase (n=26) |
Decrease (n=53) |
Increase (n=37) |
Decrease (n=36) |
Increase (n=54) |
||||
| Age | |||||||||
| ≤44 | 41 (64.1%) | 5 (19.2%) | 0.05 | 31 (58.5%) | 15 (40.5%) | 0.31 | 22(61.1%) | 22(40.7%) | 0.33 |
| >44 | 23 (35.9) | 21 (80.8%) | 22 (41.5%) | 22 (59.5%) | 14(38.9%) | 32(59.3%) | |||
| Sex | |||||||||
| Male | 32 (50.0%) | 10 (38.5%) | 0.814 | 17 (32.1%) | 25 (67.6%) | 0.07 | 12 (33.3%) | 30 (50.6%) | 0.010 |
| Female | 32 (50.0%) | 16 (61.5%) | 36 (67.9%) | 12 (32.4%) | 24 (66.7%) | 24 (44.4%) | |||
| DM | |||||||||
| Negative | 52 (81.25%) | 26 (100%) | 0.099 | 49 (92.5%) | 29 (78.4%) | 0.01 | 32 (88.9%) | 46 (85.2%) | 0.020 |
| Positive | 12 (18.75%) | 0 (0.0%) | 4 (7.5%) | 8 (21.6%) | 4 (11.1%) | 8 (14.8%) | |||
| HTN | |||||||||
| Negative | 56 (87.5%) | 18 (69.2%) | 0.605 | 45(84.9%) | 29 (78.4%) | 0.469 | 36 (100%) | 38 (70.4%) | 0.001 |
| Positive | 8 (12.5%) | 8 (30.8%) | 8 (15.1%) | 8 (21.6%) | 0 (0.0%) | 16 (29.6%) | |||
| Smoking | |||||||||
| Negative | 42 (65.6%) | 26 (100%) | 0.001 | 41 (77.4%) | 27 (73.0%) | 0.188 | 24 (66.7%) | 44 (81.5%) | 0.789 |
| Positive | 22 (34.4%) | 0 (0.0%) | 12 (22.6%) | 10 (27.0%) | 12 (33.3%) | 10 (18.5%) | |||
| FH | |||||||||
| Negative | 57 (89.1%) | 21 (80.8%) | 0.110 | 41 (77.4%) | 37 (100%) | 0.075 | 29 (80.6%) | 49 (91.7%) | 0.081 |
| Positive | 7 (10.9%) | 5 (19.2%) | 12 (22.6%) | 0 (0.0%) | 7 (19.4%) | 5 (8.3%) | |||
| PS | |||||||||
| I | 60 (93.7%) | 26 (100%) | 0.099 | 53 (100%) | 33 (89.2%) | <0.001 | 36 (100%) | 50 (92.6%) | 0.020 |
| III | 4 (6.3%) | 0 (0.0%) | 0 (0.0%) | 4 (10.8%) | 0 (0.0%) | 4 (7.4%) | |||
| T | |||||||||
| T2 | 12 (18.75%) | 8 (30.8%) | 0.004 | 16 (30.2%) | 4 (10.8%) | 0.755 | 20(55.6%) | 0(0.0%) | <0.001 |
| T3&T4 | 52 (81.25%) | 18(69.2%) | 37 (69.8%) | 33 (89.2%) | 16(44.4%) | 54 (100%) | |||
| LN | |||||||||
| Negative | 26 (40.6%) | 0 (0.0%) | 0.004 | 18 (33.9%) | 8 (21.6%) | 0.576 | 18 (50%) | 8 (14.8%) | 0.408 |
| Positive | 38 (59.4%) | 26 (100%) | 35 (66.1%) | 29 (78.4%) | 18 (50%) | 46 (85.2%) | |||
| Metastasis | |||||||||
| Negative | 49 (76.6%) | 21 (80.8%) | 0.436 | 48 (90.6%) | 22 (59.5%) | 0.013 | 31 (86.1%) | 39 (72.2%) | 0.627 |
| Positive | 15 (23.4%) | 5 (19.2%) | 5 (9.4%) | 15 (40.5%) | 5 (13.9%) | 15 (27.8%) | |||
| Site | |||||||||
| Colon | 16 (25%) | 26(100%) | <0.001 | 29 (54.7%) | 13 (35.1%) | 0.03 | 6 (16.7%) | 36 (66.7%) | 0.024 |
| Rectumb | 48 (75%) | 0(0.0%) | 24 (45.3%) | 24 (64.9%) | 30 (83.3%) | 18 (18.5%) | |||
| Toxicity | |||||||||
| GIT | 36 (64.3%) | 18 (69.2%) | 0.048 | 37 (69.8%) | 17 (58.6%) | 0.100 | 28 (77.8%) | 26 (56.5%) | 0.001 |
| HFS | 10 (17.9%) | 0 (0%) | 8 (15.1%) | 2 (6.9%) | 8 (22.2%) | 2(4.3%) | |||
| CNS | 10 (17.9%) | 8(30.8%) | 8 (15.1%) | 10 (34.5%) | 0 (0%) | 18 (39.1%) | |||
Notes: Data was presented as number and percentage of patients. aChi-square test and Fisher exact test. P<0.05 is statistically significant, and is marked with bold font. bRectum include rectosigmoid junction.
Abbreviations: COX2, cyclooxygenase2; IL6, interleukin6; IL1β, interleukin1β; DM, diabetes mellitus; HTN, hypertension; FH, family history; PS, performance status; T, tumor burden; LN, lymph nodes; GIT, gastrointestinal; HFS, hand foot syndrome; CNS, central nervous system.